FP
QNCX icon

Financial Perspectives’s Quince Therapeutics QNCX Stock Holding History

Financial Perspectives’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$241 – 732
2024
Q3 		$241 Hold
2
– – ﹤0.01% 654
2024
Q2 		$233 Hold
2
– – ﹤0.01% 652
2024
Q1 		$329 Hold
2
– – ﹤0.01% 637
2023
Q4 		$326 Hold
2
– – ﹤0.01% 664
2023
Q3 		$347 Hold
2
– – ﹤0.01% 670
2023
Q2 		$467 Hold
2
– – ﹤0.01% 647
2023
Q1 		$484 Hold
2
– – ﹤0.01% 646
2022
Q4 		$198 Hold
2
– – ﹤0.01% 663
2022
Q3 		$412 Hold
2
– – ﹤0.01% 660
2022
Q2 		$688 Hold
2
– – ﹤0.01% 642
2022
Q1 		$1.92K Hold
2
– – ﹤0.01% 613
2021
Q4 		$3.91K Buy
+2
New +$12.2K ﹤0.01% 539

Other funds holding QNCX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Perspectives's QNCX Position: Q4 2024 in Review

Financial Perspectives sold out of Quince Therapeutics (QNCX) in Q4 2024, closing a stake of 2 shares — an estimated $241 sold.

Financial Perspectives first reported a position in QNCX in Q4 2021 and held it in 12 quarters. The position peaked at $3.91K in Q4 2021. 33 funds tracked by Wall St. Rank hold QNCX as of Q4 2024.

  • Financial Perspectives reported no remaining Quince Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Financial Perspectives sold 2 Quince Therapeutics shares in Q4 2024, an estimated $241.
  • Financial Perspectives first reported a position in Quince Therapeutics in Q4 2021 and held it in 12 quarters.
  • Financial Perspectives's Quince Therapeutics position peaked at $3.91K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2024.

Based on Financial Perspectives's 13F filing for Q4 2024, filed 3 Feb 2025.